ANNA DOCKERY: Open Payments
NPI 1114705795 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,568 in 82 payments from 12 companies in 2025. Trend: 2023 $155 · 2024 $1,601 · 2025 $1,568
Food & beverage: $1,568
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $301 |
| Ipsen Biopharmaceuticals, Inc | 8 | $253 |
| Gilead Sciences, Inc. | 11 | $247 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $149 |
| GENZYME CORPORATION | 7 | $138 |
| Janssen Biotech, Inc. | 7 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $95 |
| Regeneron Healthcare Solutions, Inc. | 3 | $88 |
| Madrigal Pharmaceuticals | 4 | $68 |
| PFIZER INC. | 2 | $40 |
Products named: IQIRVO, DUPIXENT, RINVOQ, TREMFYA, RELISTOR, XIFAXAN, REZDIFFRA, LINZESS.
Industry payments across AR — which companies pay providers there.
